NASDAQ:CABA Cabaletta Bio (CABA) Stock Price, News & Analysis $3.65 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.66 +0.01 (+0.25%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cabaletta Bio Stock (NASDAQ:CABA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cabaletta Bio alerts:Sign Up Key Stats Today's Range$3.60▼$3.8550-Day Range$2.47▼$4.1552-Week Range$1.26▼$4.23Volume2.24 million shsAverage Volume5.08 million shsMarket Capitalization$595.13 millionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingModerate Buy Company Overview Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity. The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3. In parallel, Cabaletta has advanced DESCA-1 into early clinical investigation for systemic sclerosis, targeting autoreactive B cells implicated in fibrotic and vascular manifestations. These programs underscore Cabaletta’s strategy of translating its CAAR-T approach into a pipeline of precision immunotherapies for high-unmet-need autoimmune conditions. Headquartered in Philadelphia, Pennsylvania, Cabaletta Bio conducts clinical trials across the United States and Europe, collaborating with leading academic centers and biopharmaceutical partners. Since its founding in 2018, the company has built in-house capabilities for cell therapy research, process development and scalable manufacturing to support its expanding pipeline and ensure consistent production of CAAR-T products. Guided by a management team with extensive expertise in immunology, cell therapy and clinical development, Cabaletta Bio is focused on advancing its platform toward regulatory milestones and broader clinical evaluation. Through its targeted approach, the company seeks to bring transformative treatments to patients suffering from debilitating autoimmune diseases.AI Generated. May Contain Errors. Read More Cabaletta Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreCABA MarketRank™: Cabaletta Bio scored higher than 48% of companies evaluated by MarketBeat, and ranked 529th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCabaletta Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCabaletta Bio has a consensus price target of $15.50, representing about 324.7% upside from its current price of $3.65.Amount of Analyst CoverageCabaletta Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cabaletta Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cabaletta Bio are expected to grow in the coming year, from ($1.38) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cabaletta Bio is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cabaletta Bio is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCabaletta Bio has a P/B Ratio of 5.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cabaletta Bio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.81% of the float of Cabaletta Bio has been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 10.08, which indicates bearish sentiment.Change versus previous monthShort interest in Cabaletta Bio has recently increased by 5.03%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCabaletta Bio does not currently pay a dividend.Dividend GrowthCabaletta Bio does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.52 News SentimentCabaletta Bio has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cabaletta Bio this week, compared to 3 articles on an average week.Search Interest18 people have searched for CABA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows11 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cabaletta Bio insiders have not sold or bought any company stock.Percentage Held by Insiders6.44% of the stock of Cabaletta Bio is held by insiders.Percentage Held by InstitutionsCabaletta Bio has minimal institutional ownership at this time.Read more about Cabaletta Bio's insider trading history. Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CABA Stock News HeadlinesCabaletta Bio CEO Says Chemo-Free CAR T Could Unlock Big Autoimmune MarketsMay 23 at 5:07 AM | americanbankingnews.comPemphigus Vulgaris Market Analysis Report 2026-2036, Profiles of F. Hoffmann La Roche, Argenx, Sanofi, Syntimmune, Allmiral, Cabaletta Bio, and NovartisMay 21, 2026 | finance.yahoo.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 25 at 1:00 AM | Weiss Ratings (Ad)Cabaletta Bio Inc Ordinary Shares CABAMay 17, 2026 | morningstar.comMFinancial Comparison: Bicycle Therapeutics (NASDAQ:BCYC) versus Cabaletta Bio (NASDAQ:CABA)May 16, 2026 | americanbankingnews.comCabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14, 2026 | globenewswire.comCabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual MeetingMay 14, 2026 | globenewswire.comCabaletta Bio (CABA) Expected to Announce Earnings on ThursdayMay 14, 2026 | americanbankingnews.comSee More Headlines CABA Stock Analysis - Frequently Asked Questions How have CABA shares performed this year? Cabaletta Bio's stock was trading at $2.19 at the beginning of the year. Since then, CABA shares have increased by 66.7% and is now trading at $3.65. How were Cabaletta Bio's earnings last quarter? Cabaletta Bio, Inc. (NASDAQ:CABA) issued its quarterly earnings data on Thursday, May, 14th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.02. When did Cabaletta Bio IPO? Cabaletta Bio (CABA) raised $102 million in an initial public offering on Friday, October 25th 2019. The company issued 6,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO. Who are Cabaletta Bio's major shareholders? Top institutional shareholders of Cabaletta Bio include Jennison Associates LLC (8.06%), Renaissance Technologies LLC (1.83%), Dimensional Fund Advisors LP (0.67%) and Bank of America Corp DE (0.24%). Insiders that own company stock include Steven Nichtberger, Mark Simon, Gwendolyn Binder, Gwendolyn Binder, Shawn Tomasello, Steve Gavel, David J Chang and Michael Gerard. View institutional ownership trends. How do I buy shares of Cabaletta Bio? Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cabaletta Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cabaletta Bio investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF), Jabil (JBL) and Disc Medicine (IRON). Company Calendar Last Earnings5/14/2026Today5/24/2026Jefferies Global Healthcare Conference 20266/03/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/08/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CABA's financial health is in the Green zone, according to TradeSmith. CABA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CABA CIK1759138 Webwww.cabalettabio.com Phone267-759-3100FaxN/AEmployees50Year Founded2017Price Target and Rating Average Price Target for Cabaletta Bio$15.50 High Price Target$30.00 Low Price Target$4.00 Potential Upside/Downside+324.7%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$167.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-131.58% Return on Assets-96.46% Debt Debt-to-Equity RatioN/A Current Ratio2.95 Quick Ratio2.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book5.79Miscellaneous Outstanding Shares163,050,000Free Float152,554,000Market Cap$595.13 million OptionableOptionable Beta3.18 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CABA) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
